Onkologischer Schwerpunkt Am Oskar Helene Heim MVZ

The Onkologischer Schwerpunkt Am Oskar Helene Heim MVZ conducts studies focused on colon cancer and rectal cancer, aiming to improve post‑surgical outcomes through targeted adjuvant strategies.

• Adjuvant therapy guided by circulating tumor DNA (ctDNA) after resection of stage II colon cancer
• Evaluation of disease‑free survival in patients receiving postoperative chemotherapy for metastatic colorectal cancer
• Comparison of active chemotherapy versus structured follow‑up in metastatic colorectal disease

With four active trials and two investigators, the site blends clinical expertise with innovative trial designs to enhance treatment options for patients with gastrointestinal malignancies.

Research at this Berlin centre also addresses hematologic and squamous cell neoplasms, including investigations of myelodysplastic syndromes and anal carcinoma.

• Assessment of erythroid response to canakinumab in lower‑risk MDS/MDS‑MPN
• Integration of the PD‑L1 inhibitor durvalumab with chemoradiotherapy for locally‑advanced anal cancer
• Analysis of disease‑free survival improvements with immune checkpoint blockade in anal carcinoma

These studies reflect a commitment to exploring both novel immunotherapies and supportive treatments to raise cure rates across a range of tumor types.

Beyond specific disease categories, the MVZ Onkologischer Schwerpunkt advances oncology care by testing innovative therapeutic concepts and diagnostic tools across multiple tumor sites.

• Phase II evaluation of canakinumab for anemia management in MDS patients
• Randomized multicenter trial of post‑resection/ablation chemotherapy in metastatic colorectal cancer (FIRE‑9)
• Prospective trial investigating ctDNA‑driven adjuvant therapy decisions in colon cancer

The collaborative environment, supported by two dedicated investigators, enables rapid translation of research findings into clinical practice for the benefit of the Berlin community.